BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Sells 84,310 Shares of STERIS plc (NYSE:STE)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp cut its position in STERIS plc (NYSE:STE - Free Report) by 38.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 136,682 shares of the medical equipment provider's stock after selling 84,310 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned about 0.14% of STERIS worth $28,096,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in STE. Avalon Trust Co purchased a new position in STERIS in the 4th quarter valued at approximately $30,000. Human Investing LLC purchased a new position in shares of STERIS in the fourth quarter valued at $31,000. Anfield Capital Management LLC raised its stake in shares of STERIS by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock valued at $37,000 after purchasing an additional 91 shares during the period. Manchester Capital Management LLC lifted its holdings in STERIS by 182.7% during the 4th quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock worth $44,000 after purchasing an additional 137 shares in the last quarter. Finally, Brown Brothers Harriman & Co. lifted its holdings in STERIS by 66.7% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 88 shares in the last quarter. Hedge funds and other institutional investors own 94.69% of the company's stock.

STERIS Price Performance

STERIS stock traded up $2.70 during mid-day trading on Tuesday, hitting $245.70. 104,539 shares of the company traded hands, compared to its average volume of 541,931. STERIS plc has a one year low of $200.98 and a one year high of $252.79. The stock has a market cap of $24.14 billion, a price-to-earnings ratio of 52.17 and a beta of 0.96. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.40 and a current ratio of 2.13. The stock has a fifty day moving average price of $226.61 and a 200-day moving average price of $220.26.

STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.15. STERIS had a net margin of 8.66% and a return on equity of 13.91%. The firm had revenue of $1.48 billion for the quarter, compared to analysts' expectations of $1.47 billion. During the same quarter last year, the company posted $2.58 EPS. The business's quarterly revenue was up 5.7% on a year-over-year basis. On average, equities analysts predict that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 26th. Shareholders of record on Tuesday, June 10th will be paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 0.93%. The ex-dividend date of this dividend is Tuesday, June 10th. STERIS's dividend payout ratio (DPR) is currently 36.77%.

Analyst Ratings Changes

Several brokerages have recently weighed in on STE. Morgan Stanley upped their price target on STERIS from $240.00 to $260.00 and gave the company an "equal weight" rating in a research report on Monday, May 19th. Citigroup reaffirmed an "outperform" rating on shares of STERIS in a research note on Friday, May 16th. Stephens reiterated an "overweight" rating and issued a $250.00 target price on shares of STERIS in a research note on Thursday, May 15th. Piper Sandler raised their price target on shares of STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a report on Monday, April 7th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $264.00.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.